Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting
TITUSVILLE, N.J. – October 14, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.Data presentations from eight abstracts will provide additional evidence supporting the role of objective multiparameter risk assessment approaches in helping to optimize treatment and care for pulmonary arterial hypertension (PAH), as well as the impact of earlier and comprehensive therapy with ...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

STOP-DAPT 2 ACS: 1 Month of DAPT Inadequate After Recent ACS STOP-DAPT 2 ACS: 1 Month of DAPT Inadequate After Recent ACS
Findings from a Japanese trial show 1 month of dual antiplatelet therapy and 11 months of clopidogrel monotherapy is inferior to 12 months of DAPT in patients undergoing PCI after acute coronary syndrome.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 3, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) e...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

TALOS-AMI: Switching From Ticagrelor to Clopidogrel Safe Post-PCI TALOS-AMI: Switching From Ticagrelor to Clopidogrel Safe Post-PCI
De-escalation of dual-antiplatelet therapy after 30 days reduced major cardiac events without an uptick in ischemic risk in the Korean study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 21, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

HOST-EXAM: Clopidogrel Beats Aspirin as Monotherapy After Stenting HOST-EXAM: Clopidogrel Beats Aspirin as Monotherapy After Stenting
For patients who had completed a period of dual antiplatelet therapy, clopidogrel alone was linked to lower rates of both ischemic events and bleeding compared to aspirin.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 17, 2021 Category: Neurology Tags: Cardiology News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Real-World Observational Analysis of UPTRAVI ® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
SOUTH SAN FRANCISCO, CA – April 6, 2021 – Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with UPTRAVI® (selexipag) either maintained (56%) or reduced (20%) their one-year mortality risk score. The SPHERE results were published in the April issue of the Journal of Heart and Lung Transplantation (JHLT). SPHERE is an ongoing real-world, observational, user registry using two different risk assessment methods that describes the clinical characte...
Source: Johnson and Johnson - April 6, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clopidogrel Bests Ticagrelor for Elective PCI Clopidogrel Bests Ticagrelor for Elective PCI
Ticagrelor failed to unseat clopidogrel as the guideline-recommended P2Y12 inhibitor of choice in patients undergoing elective percutaneous coronary intervention for stable CAD in the randomized ALPHEUS trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

No Migraine'Rebound' Stopping Clopidogrel After ASD Closure No Migraine'Rebound' Stopping Clopidogrel After ASD Closure
Some concern has been raised that stopping DAPT too soon may increase migraine risk, but a new study offers reassuring findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 6, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI ® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
SOUTH SAN FRANCISCO, CA – September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UPTRAVI® (selexipag) as an injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults with WHO functional class (FC) II–III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy. In patients with PAH, interruptions in treatment should be avoided due to the progressive nature of the disease...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Elderly May Not Reap Post-MI Ticagrelor Advantage vs Clopidogrel Elderly May Not Reap Post-MI Ticagrelor Advantage vs Clopidogrel
The PLATO trial's seminal results a decade ago may not apply to all patients after a myocardial infarction; a large registry study suggests no ticagrelor benefit, perhaps even harm, in older patients.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 9, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Aspirin Alone Preferred Antithrombotic Strategy After TAVI Aspirin Alone Preferred Antithrombotic Strategy After TAVI
Aspirin alone after TAVI significantly reduced bleeding compared with aspirin plus clopidogrel, without increasing thromboembolic events, in the latest results from the POPular TAVI study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI Fewer GI Bleeds With Ticagrelor and Prasugrel After PCI
In a comparison of post-PCI antiplatelet medications, ticagrelor or prasugrel were associated with fewer GI bleeding events than clopidogrel.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 26, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Antithrombotic Therapies in COVID-19 Disease: a Systematic Review
Conclusion(s): New evidence on thromboembolism in COVID-19 does not warrant a change in current guidance on thromboprophylaxis among hospitalized patients. Prospective trials of antithrombotic treatment strategies among patients with COVID-19 are urgently needed. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 1, 2020 Category: Consumer Health News Source Type: news

ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights ACC Virtual Scientific Sessions 2020: Interventional Strategies Highlights
Genetic testing for clopidogrel resistance and a new strategy for atrial fibrillation ablation are among the highlights from the virtual ACC scientific sessions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 28, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin Mislabeled Clopidogrel Lot Recalled, May Contain Simvastatin
International Laboratories has recalled one lot of clopidogrel tablets packaged in bottles of 30 tablets because it may contain simvastatin instead of clopidogrel.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 17, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy
Investigators from the TAILOR PCI trial that used point-of-care genomic testing to identify clopidogrel nonresponders discuss the take-homes and why genotyping may be better than platelet function tests.Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes. (Source: WebMD Health)
Source: WebMD Health - April 6, 2020 Category: Consumer Health News Source Type: news

VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin VOYAGER PAD: Clopidogrel Adds No Benefit to Rivaroxaban+Aspirin
Adding clopidogrel added no efficacy but caused additional bleeding episodes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF Safe to Skip Post-TAVR Clopidogrel in Patients on OAC for AF
The bleeding risk went up in such patients on oral anticoagulation who then added clopidogrel in POPULAR-TAVI, and being on OAC alone didn't raise ischemic risk. Some experts question its methods.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 30, 2020 Category: Surgery Tags: Cardiology News Source Type: news

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint TAILOR-PCI: Clopidogrel Genotyping Trial Narrowly Misses Endpoint
The trial missed its ambitious primary endpoint of a 50% reduction in cardiovascular events, but commentators felt nonetheless that it shows a clinical benefit and should change practice.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 28, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

More Concern Over Morphine, Clopidogrel Interaction in ACS More Concern Over Morphine, Clopidogrel Interaction in ACS
New data suggest use of morphine delays the absorption of clopidogrel and leads to an increase in short-term cardiac ischemic events.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 23, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Clopidogrel Appropriate for PCI in Liver Transplant Candidates Clopidogrel Appropriate for PCI in Liver Transplant Candidates
In patients with decompensated cirrhosis undergoing percutaneous coronary intervention (PCI), clopidogrel safely inhibits platelet aggregation, according to a small study of liver-transplant candidates.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 8, 2020 Category: Surgery Tags: Cardiology News Source Type: news

Genetic Testing Spots Clopidogrel Responders After PCI for STEMI Genetic Testing Spots Clopidogrel Responders After PCI for STEMI
Guidelines for the management of acute STEMI patients undergoing PCI may need to be revised after a genotype-guided protocol giving clopidogrel to responders reduced bleeding rates, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 3, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Optimal Dual Antiplatelet Duration After Minor Stroke or TIA? Optimal Dual Antiplatelet Duration After Minor Stroke or TIA?
Pooled data from two large trials points to a net benefit associated with 21 days of clopidogrel – aspirin therapy after a minor stroke or transient ischemic attack.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 29, 2019 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news

Ultrasound-Guided Thoracentesis Appears Safe With Novel Oral Anticoagulants or Clopidogrel Ultrasound-Guided Thoracentesis Appears Safe With Novel Oral Anticoagulants or Clopidogrel
Rates of significant bleeding complications are very low after ultrasound-guided thoracentesis in patients on novel oral anticoagulants (NOACs) and/or clopidogrel, a retrospective analysis found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 6, 2019 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

clopidogrel bisulfate (Plavix)
Title: clopidogrel bisulfate (Plavix)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 7/30/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 30, 2019 Category: Cardiology Source Type: news

Plavix (clopidogrel) vs. Xarelto (rivaroxaban)
Title: Plavix (clopidogrel) vs. Xarelto (rivaroxaban)Category: MedicationsCreated: 7/19/2019 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 19, 2019 Category: Cardiology Source Type: news

Plavix (clopidogrel) vs. Effient (prasurgrel)
Title: Plavix (clopidogrel) vs. Effient (prasurgrel)Category: MedicationsCreated: 7/19/2019 12:00:00 AMLast Editorial Review: 7/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 19, 2019 Category: Cardiology Source Type: news

Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes - Scotti P, S éguin C, Lo BWY, De Guise E, Troquet JM, Marcoux J.
OBJECTIVE: Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weig... (Source: SafetyLit)
Source: SafetyLit - July 8, 2019 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Plavix (clopidogrel) vs. Coumadin (warfarin)
Title: Plavix (clopidogrel) vs. Coumadin (warfarin)Category: MedicationsCreated: 6/25/2019 12:00:00 AMLast Editorial Review: 6/25/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 25, 2019 Category: Cardiology Source Type: news

clopidogrel (Plavix) vs. heparin (Hemochron)
Title: clopidogrel (Plavix) vs. heparin (Hemochron)Category: MedicationsCreated: 6/24/2019 12:00:00 AMLast Editorial Review: 6/24/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 24, 2019 Category: Cardiology Source Type: news

Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half
Restarting antiplatelet therapy after intracranial hemorrhage remains controversial, but new evidence suggests aspirin or clopidogrel can significantly reduce recurrent ICH without increased bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 23, 2019 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Aspirin, Anti-Clotting Meds Safe After Bleeding Stroke: Study
WEDNESDAY, May 22, 2019 -- Taking aspirin or anti-clotting medicines like Plavix won't boost the risk of another stroke if you've already survived a bleeding stroke, a new study suggests. In fact, they might even help guard against a second brain... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 22, 2019 Category: General Medicine Source Type: news

International Laboratories, LLC Issues Voluntary Nationwide Recall of one (1) Lot of Clopidogrel Tablets USP, 75 mg packaged in bottles of 30 tablets Due to Mislabeling NDC # 54458-888-16; Lot # 117099A
International Laboratories, LLC is voluntarily recalling Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Clopidogrel tablets USP 75 mg but may contain Clopidogrel 75mg or Simvastatin Tablets USP 10 mg. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New Studies Support Dropping Long-term Aspirin After Stenting New Studies Support Dropping Long-term Aspirin After Stenting
The STOPDAPT-2 and SMART-CHOICE trials both suggest extended therapy with clopidogrel or another P2Y12 inhibitor alone may be preferable to dual antiplatelet therapy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 28, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Ticagrelor is as safe and effective as clopidogrel after heart attack
(American College of Cardiology) Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Stopping aspirin three months after stenting does not increase risk of death
(American College of Cardiology) Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Stopping DAPT after one-month improved outcomes in stent patients
(American College of Cardiology) Patients who stopped taking aspirin one month after receiving a stent in the heart's arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Drug May Be Safer Option Against Repeat Stroke
The risk of another stroke caused by a blood clot was halved for patients who took the drug Pletal plus aspirin or clopidogrel, versus those who took aspirin or clopidogrel alone. (Source: WebMD Health)
Source: WebMD Health - February 7, 2019 Category: Consumer Health News Source Type: news

Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke
New results show cilostazol plus aspirin or clopidogrel reduced recurrent stroke rate by half over aspirin or clopidogrel alone in high-risk stroke patients without increased bleeding.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Blood Thinning Drug May Be Safer Option Against Recurrent Stroke
THURSDAY, Feb. 7, 2019 -- Taking the blood thinner Pletal (cilostazol) with either aspirin or clopidogrel (best known as Plavix) lowers stroke patients'risk of a subsequent stroke better than taking aspirin or clopidogrel alone, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 7, 2019 Category: General Medicine Source Type: news

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news